Skip to content

Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI

Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03039166
Enrollment
260
Registered
2017-02-01
Start date
2017-05-31
Completion date
2022-10-31
Last updated
2017-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Diseases

Brief summary

the investigators hypothesize that hub alteration occurs both in diffuse diseases (MS, AD) as well as in more 'network specific' diseases (Parkinson, ALS, Epilepsy). This could impact on functional dysfunction not directly related to each disease, but that could induce common syndrome such as cognitive impairment observed in Parkinson, partial epilepsy or ALS. The objective here is to test this hypothesis and provides better understandings on pathophysiological processes affecting those highly connected regions in 'diffuse' and 'focal' neurological diseases. The ultimate goal is to identify new clinical targets for trans-nosological approaches (DBS, cognitive rehabilitation ...). Practically, the investigators will explore 200 patients classified in 5 cohorts of 40 patients suffering for MS, AD, Parkinson, ALS, Epilepsy, using the last advanced methods to assess structural and functional brain connectivity implemented on the human 7T MR scanner equipping the CEMEREM (CHU Timone, Marseille, only 50 similar MR scanners worldwide). In addition to high resolution diffusion MRI and rs-fMRI, metabolic and ionic (sodium) mapping will complement the MR protocol to characterize the pathophysiological processes of hub injury. Sixty healthy controls will also be explored wih the same protocol for normal database. The proposal aims at characterizing and comparing from a morphological-functional point of view, the hub regions of patients suffering from these five diseases, to demonstrate the pertinence to preserve hub integrity as a major therapeutic target whatever the disease.

Interventions

DEVICEMRI 7T
DEVICEMRI 3 T
BIOLOGICALblood sample

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Person female or male, more than 18-year-old, * Person presenting unchecked general disease such as severe cancer, autoimmune disease, hepatic insufficiency, severe or untreated, shady arterial high blood pressure of the conduction or the disorder of the rhythm * Person presenting chronic psychiatric disease, insane syndrome. * Person presenting contraindication to the realization of an examination by MRI (metallic claustrophobia, foreign body, pacemakers), * Person benefiting from a social security cover, * Person having read, understood and signed an informed consent after information

Exclusion criteria

* Claustrophobia, * Metallic foreign bodies, * Pacemakers, * Severe renal insufficiency

Design outcomes

Primary

MeasureTime frame
Index of reorganization of the structural hubs (ks-Degree)5years

Secondary

MeasureTime frame
Concentrations of sodium within hubs5 years
Concentrations of Glutamate/Glutamine within hubs5 years
cortical Thicknesses within hubs5 years
Iron accumulation within hubs5 years

Countries

France

Contacts

Primary Contactmaxime GUYE
maxime.guye@ap-hm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026